Clinical Trial

All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Study acronym: DREAMM 8
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with that of combination of pomalidomide, bortezomib and dexamethasone in Japanese participants with relapsed/refractory multiple myeloma (RRMM).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-25; most recent amendment 2026-05-25.
Trial Details
NCT Number NCT06956170
Lead Sponsor GlaxoSmithKline
Conditions Multiple Myeloma
Enrollment 21 participants
Start Date 2022-02-10
Primary Completion 2024-05-27 (estimated)
Study Completion 2029-06-25 (estimated)
Updated on ClinicalTrials.gov 2026-06-12